Metabasis Therapeutics, Inc. Presents Preclinical Data on CS-917 and MB07811 at the American Diabetes Association Meeting

SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq:MBRX), a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of metabolic and liver diseases by targeting the liver and liver pathways, announced today that the Company presented two posters at the 67th scientific sessions of the American Diabetes Association (ADA) in Chicago. The posters, entitled, “MB06322 (CS-917), But Not Metformin, Lowers Blood Glucose by Inhibiting Gluconeogenesis in Zucker Diabetic Fatty Rats,” and “MB07811, a Liver-Targeted Prodrug of a Novel Thyroid Hormone Receptor Agonist, Lowers Plasma Cholesterol in Cynomolgus Monkeys as Effectively as Atorvastatin,” were presented on Sunday, June 24th. Two other posters on CS-917 and one abstract will be presented at ADA by Metabasis’ partner, Daiichi Sankyo.